ATE358497T1 - Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte - Google Patents

Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte

Info

Publication number
ATE358497T1
ATE358497T1 AT97122186T AT97122186T ATE358497T1 AT E358497 T1 ATE358497 T1 AT E358497T1 AT 97122186 T AT97122186 T AT 97122186T AT 97122186 T AT97122186 T AT 97122186T AT E358497 T1 ATE358497 T1 AT E358497T1
Authority
AT
Austria
Prior art keywords
cells
spongiform encephalopathy
products
cell
therapy
Prior art date
Application number
AT97122186T
Other languages
English (en)
Inventor
Adriano Aguzzi
Michael A Klein
Alex Raeber
Charles Weissmann
Rolf Zinkernagel
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE358497T1 publication Critical patent/ATE358497T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AT97122186T 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte ATE358497T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97122186A EP0931551B1 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Publications (1)

Publication Number Publication Date
ATE358497T1 true ATE358497T1 (de) 2007-04-15

Family

ID=8227810

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie

Country Status (9)

Country Link
US (1) US20080063600A1 (de)
EP (4) EP1215497B1 (de)
JP (1) JP2002508335A (de)
AT (3) ATE427120T1 (de)
AU (1) AU2613199A (de)
CA (1) CA2348660A1 (de)
DE (3) DE69737557T2 (de)
ES (3) ES2324334T3 (de)
WO (1) WO1999030738A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053838A2 (en) * 1997-05-30 1998-12-03 Winnacker Ernst Ludwig A soluble laminin receptor precursor and methods to inhibit its interactions
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
EP1921451A3 (de) 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
US20070166735A1 (en) * 2005-12-08 2007-07-19 South Dakota State University Methods of in vitro propagation and detection of infectious prion
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
JP2010530857A (ja) * 2007-06-22 2010-09-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用
RU2368905C1 (ru) * 2008-07-11 2009-09-27 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ диагностики степени тяжести диабетической энцефалопатии у детей и подростков
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
ES2954311T3 (es) 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273882A (en) 1985-06-13 1993-12-28 Amgen Method and kit for performing nucleic acid hybridization assays
US5055290A (en) 1985-12-18 1991-10-08 Boehringer Mannehim Gmbh Ciamexone as a selective immunosuppressant
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
US5369119A (en) 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
ATE420355T1 (de) 2009-01-15
DE69737557D1 (de) 2007-05-16
JP2002508335A (ja) 2002-03-19
WO1999030738A3 (en) 1999-10-21
EP1214943B1 (de) 2009-04-01
ES2320314T3 (es) 2009-05-21
EP1044020A2 (de) 2000-10-18
EP0931551A1 (de) 1999-07-28
EP1215497B1 (de) 2009-01-07
US20080063600A1 (en) 2008-03-13
WO1999030738A2 (en) 1999-06-24
EP1215497A1 (de) 2002-06-19
CA2348660A1 (en) 1999-06-24
DE69739210D1 (de) 2009-02-26
ES2285720T3 (es) 2007-11-16
EP0931551B1 (de) 2007-04-04
ES2324334T3 (es) 2009-08-05
DE69739344D1 (de) 2009-05-14
EP1214943A1 (de) 2002-06-19
DE69737557T2 (de) 2007-12-20
AU2613199A (en) 1999-07-05
ATE427120T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE69737557D1 (de) Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte
IL186495A (en) Use of disaccharide-based compounds for the manufacture of medicaments without an exogenous antigen for prophylactic and therapeutic treatment of infectious and other diseases
DK0430474T3 (da) Præparater med vedvarende frigivelse til behandling af periodontal sygdom
NO931372L (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
EP0915648A4 (de)
CY1107550T1 (el) Συνδυαστικα εμβολια μηνιγγιτιδας b/c
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
DE60118743D1 (de) Methode zur behandlung und prävention von ansteckenden krankheiten
EP0671175A3 (de) Pharmazeutische Zubereitungen mit verzögerter Freisetzung zur Behandlung periodontaler Erkrankungen.
DE69832688D1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
ATE243750T1 (de) Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
IT8803460A0 (it) Metodo ed apparecchiatura per la sterilizzazione e la pulizia meccanica di attrezzi medici, chirurgici odontoiatrici quali manipoli, specchietti, bisturi e simili
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
EP0674905A3 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung.
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
ID16598A (id) Metode pencegahan dan pengobatan penyakit-penyakit infeksi virus
ATE132374T1 (de) Verhütung und behandlung einer retrovirenkrankheit
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties